Literature DB >> 26484962

Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer.

Helen Blackburn1, Sandra West.   

Abstract

BACKGROUND: Transarterial chemoembolization (TACE) is an established treatment in managing liver primary neoplasms or liver metastases. Postembolization syndrome (PES) is a common adverse event defined as fever without associated sepsis, pain in the right upper quadrant, and nausea and/or vomiting.
OBJECTIVE: This integrative review aims to identify effective management strategies for PES or one of its characterizing symptoms (fever, pain, and nausea and/or vomiting).
METHODS: Searches of electronic databases MEDLINE, EMBASE, and CINAHL were conducted. Fifteen articles were identified for inclusion. Seven addressed all symptoms of PES, and 8 studies focused on individual symptoms of PES.
RESULTS: Interventions identified are intra-arterial lidocaine, oral and intravenous analgesics, steroids, wrist-ankle acupuncture, antibiotics, and 5-HT3 receptor antagonists. Findings are explicated according to individual symptoms of PES. Intra-arterial lidocaine, steroids, and a 5-HT3 receptor antagonist are found to offer potential benefit in the management of PES symptoms.
CONCLUSION: A number of interventions have shown potential benefit in the management of PES. A systemic approach using combination therapy is necessary to effectively manage characterizing symptoms. Further research is needed to determine the impact of primary disease site, TACE technique, and chemotherapeutic agent on PES. IMPLICATIONS FOR PRACTICE: Oncology nurses are uniquely placed to undertake thorough patient assessment after TACE and implement early intervention to effectively manage PES.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26484962     DOI: 10.1097/NCC.0000000000000302

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  22 in total

1.  Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma-is prophylactic dexamethasone useful, or not?

Authors:  Toru Ishikawa
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

2.  Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.

Authors:  Yanqin Wu; Wenzhe Fan; Miao Xue; Bihui Zhong; Shenghong Zhang; Yu Wang; Wang Yao; Yue Zhao; Jiaping Li
Journal:  Oncologist       Date:  2019-06-27

3.  Impact of discriminant factors on the comfort-care of nurses caring for trans-arterial chemoembolisation patients.

Authors:  Myoung Soo Kim; Ju-Yeon Uhm
Journal:  Support Care Cancer       Date:  2022-06-16       Impact factor: 3.359

4.  Effectiveness of Transarterial Embolization in Treatment of Symptomatic Hepatic Hemangiomas: Systematic Review and Meta-analysis.

Authors:  Pooya Torkian; Jianjun Li; John A Kaufman; Younes Jahangiri
Journal:  Cardiovasc Intervent Radiol       Date:  2020-08-17       Impact factor: 2.740

5.  Paraplegia after transcatheter artery chemoembolization in a child with clear cell sarcoma of the kidney: A case report.

Authors:  Jia-Bin Cai; Min He; Fa-Liang Wang; Jie-Ni Xiong; Jun-Qing Mao; Zhong-Hai Guan; Lin-Jie Li; Jin-Hu Wang
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

Review 6.  Treatment of Primary Liver Tumors and Liver Metastases, Part 2: Non-Nuclear Medicine Techniques.

Authors:  Francois H Cornelis; Stephen B Solomon
Journal:  J Nucl Med       Date:  2018-10-25       Impact factor: 10.057

7.  Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis.

Authors:  Haohao Lu; Chuansheng Zheng; Bin Liang; Bin Xiong
Journal:  BMC Cancer       Date:  2021-05-07       Impact factor: 4.430

8.  Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Seung Ji Kang; Uh Jin Kim; Seong Eun Kim; Joon Hwan An; Mi Ok Jang; Dae-Seong Myung; Kyung-Hwa Park; Sook-In Jung; Sung Bum Cho; Hee-Chang Jang; Young Eun Joo
Journal:  Dis Markers       Date:  2018-04-17       Impact factor: 3.434

9.  Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.

Authors:  Haohao Lu; Chuansheng Zheng; Bin Liang; Bin Xiong
Journal:  BMC Gastroenterol       Date:  2021-06-11       Impact factor: 3.067

10.  Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.

Authors:  Li-Fang Bian; Xue-Hong Zhao; Bei-Lei Gao; Sheng Zhang; Guo-Mei Ge; Dong-Di Zhan; Ting-Ting Ye; Yan Zheng
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.